These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 11192869)
1. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. Montaner JS; Harrigan PR; Jahnke N; Raboud J; Castillo E; Hogg RS; Yip B; Harris M; Montessori V; O'Shaughnessy MV AIDS; 2001 Jan; 15(1):61-9. PubMed ID: 11192869 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277 [TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
4. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086 [TBL] [Abstract][Full Text] [Related]
5. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV. Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608 [TBL] [Abstract][Full Text] [Related]
6. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up. Clevenbergh P; Durant J; Halfon P; del Giudice P; Mondain V; Montagne N; Schapiro JM; Boucher CA; Dellamonica P Antivir Ther; 2000 Mar; 5(1):65-70. PubMed ID: 10846595 [TBL] [Abstract][Full Text] [Related]
7. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study. Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586 [TBL] [Abstract][Full Text] [Related]
8. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. Harrigan PR; Hertogs K; Verbiest W; Pauwels R; Larder B; Kemp S; Bloor S; Yip B; Hogg R; Alexander C; Montaner JS AIDS; 1999 Oct; 13(14):1863-71. PubMed ID: 10513644 [TBL] [Abstract][Full Text] [Related]
9. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E; Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227 [TBL] [Abstract][Full Text] [Related]
10. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice. Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A; J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785 [TBL] [Abstract][Full Text] [Related]
11. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients. Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D; Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699 [TBL] [Abstract][Full Text] [Related]
12. Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire. Adjé-Touré C; Celestin B; Hanson D; Roels TH; Hertogs K; Larder B; Diomande F; Peeters M; Eholié S; Lackritz E; Chorba T; Nkengasong JN AIDS; 2003 Jul; 17 Suppl 3():S23-9. PubMed ID: 14565606 [TBL] [Abstract][Full Text] [Related]
14. Time trends in primary HIV-1 drug resistance among recently infected persons. Grant RM; Hecht FM; Warmerdam M; Liu L; Liegler T; Petropoulos CJ; Hellmann NS; Chesney M; Busch MP; Kahn JO JAMA; 2002 Jul; 288(2):181-8. PubMed ID: 12095382 [TBL] [Abstract][Full Text] [Related]
15. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team. Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Ait-Khaled M; Purdon S AIDS; 2000 May; 14(7):781-9. PubMed ID: 10839585 [TBL] [Abstract][Full Text] [Related]
16. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa. van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793 [TBL] [Abstract][Full Text] [Related]